FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices.
نویسندگان
چکیده
منابع مشابه
Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.
CONTEXT Left ventricular (LV) systolic dysfunction causes substantial morbidity and mortality, even with optimal pharmacotherapy. Atrial-synchronized biventricular pacemakers (cardiac resynchronization therapy [CRT]) received US Food and Drug Administration (FDA) approval for use in selected patients with LV systolic dysfunction in 2001. OBJECTIVE To summarize the current evidence base for th...
متن کاملRecent Developments in Geopolitics of Energy and their Effects on the Political and Economic Future of the Middle East Countries
Energy has always been of particular importance to humanity. Oil and gas have been some of the energies that greatly influenced the national security of countries, which produce and consume energy. With the transformation of geostrategic discourse into geo-economic discourse in recent decades and the key role of economics in global relations, oil as the basis of modern industry has enjoyed a hi...
متن کاملTantalum/ Nitrogen and n-type WO3 semiconductor/FTO structures as a cathode for the future of nano devices
In the last decades an important number of research papers published on nano chip electrode and cathode electrochromic materials. Tantalum (Ta) with so high melting point can be as a good candidate for the future of nano chip devices. However, its surface has not enough trap centers and/or occupation states, so nitrogen ions exposed on Ta surafce, may solve this problem. For this purpose, in th...
متن کاملCurrent Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review
Pheochromocytomas (PCCs) are rare neuroendocrine tumors. The current diagnostic tools are based on biochemistry and histopathology results, but heterogeneity of diagnostic markers, signs and symptoms of PCCs bring a lot of difficulties for these two current methods. Unfortunately microscopic understanding of PCCs is not adequate for its confident prognosis and management. There are data linking...
متن کاملTrials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process
INTRODUCTION Transvaginal mesh devices are approved in the USA by the Food and Drug Administration (FDA), through the 510(k) system. However, there is uncertainty about the benefit to harm balance of mesh approved for pelvic organ prolapse. We, therefore, assessed the evidence at the time of approval for transvaginal mesh products and the impact of safety studies the FDA mandated in 2012 becaus...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cardiovascular revascularization medicine : including molecular interventions
دوره 18 4 شماره
صفحات -
تاریخ انتشار 2017